Table 1. Phase III clinical trials of bevacizumab combinations with chemotherapy in stage IIIB/IV NSCLC.

First author	Parameter	Control arm	Bevacizumab 7.5 mg/kg	Bevacizumab 15 mg/kg	P value
Sandler (26)	N=878	Carboplatin Paclitaxel
	Response	15%	-	35%	<0.001
	PFS	4.5 months	-	6.2 months	<0.001
	OS	10.3 months	-	12.3 months	0.003
Reck (28)	N=1043	Cisplatin Gemctabine
	Response	20.1%	34.1%	30.4%	<0.0001* 0.0023**
	PFS	6.1 months	6.7 months	6.5 months	0.0001* 0.002**
	OS	13.1 months	13.6 months	13.4 months	0.37* 0.84**

*P value for the analysis of 7.5 mg/kg of bevacizumab and placebo; **P value for the analysis of 7.5 mg/kg and 15 mg/kg of bevacizumab